OncoQR ML offers different partnering opportunities, both on technology and product level:

Its proprietary S-TIR-Platformis available for licensing on a target-by-target basis. With its scientifically validated Proof of Concept (PoC), it offers the chance to rapidly develop new vaccines from design to PoC within 9 to 12 months. The lead candidate OQR200 is available for licensing: It triggers an active, reversible and appropriate immune response without side effects. A pre-clinical information package will be made available under CDA. Outstanding results on scientific research are available since September 2017.

The lead candidate TYG100 is also available for licensing through TYG oncology Ltd.

Download Non-confidential Information Folder here

Download Non-confidential Company Presentation here